Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trials

CONCLUSION: Reporting of subsequent cycle toxicity is uncommon in oncology phase I clinical trial publications and becoming less common over time. Guidelines for reporting of phase I oncology clinical trials should expand to include toxicity data beyond the first cycle.PMID:37961910 | DOI:10.1177/17407745231210872

Source: Clinical Trials - November 14, 2023 Category: Research Authors: Avina Rami Steven G DuBois Kevin Campbell Source Type: research